Emery P, Vlahos B, Szczypa P, et al. - Utilizing observational data from patients with rheumatoid arthritis (RA), researchers assessed long-term drug survival (proportion of patients still receiving treatment) and discontinuation of etanercept (ETN), infliximab, adalimumab, certolizumab pegol, and golimumab (GOL). Following a systematic literature review, drug survival was estimated at 12 and 12–24 months of followup by summing up the proportions of patients continuing treatment and dividing by number of studies. Through Metaprop, drug survival at ≥ 36 months of followup was estimated. One hundred seventy publications have been included. More patients with RA receiving ETN remain on treatment after > 12 months of followup compared with other tumor necrosis factor inhibitors.